Cited by 4,319Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and StudiesRenal cell carcinoma treatment

The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Open access

Reig, Maria, Forner, Alejandro, Rimola, Jordi, Ferrer-Fàbrega, Joana, Burrel, Marta, Garcia-Criado, Ángeles, Kelley, Robin K., Galle, Peter R., Mazzaferro, Vincenzo, Salem, Riad, Sangro, Bruno, Singal, Amit G., Vogel, Arndt, Fuster, Josep, Ayuso, Carmen, Bruix, Jordi·2022·Journal of Hepatology

DOI 10.1016/j.jhep.2021.11.018PMC PMC8866082

Open this paper in CoChat — free account Open PDF

Abstract

There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2021.11.018

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citation
Preoperative assessment of liver function: a comparison of 99mTc‐Mebrofenin scintigraphy with indocyanine green clearance test
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citation
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citation
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173
Self-citation
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Hepatocellular carcinoma
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,774
Self-citation
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586

Show all 136 references

Sorted by citations

Items 101–200 of 1,000

Survival Outcomes Among Patients With Hepatocellular Carcinoma in a Large Integrated US Health System
Yilma, M., Xu, R. H., Saxena, V., Muzzin, M., Tucker, L.-Y. S., Lee, J. D., Mehta, N. J., & Mukhtar, N. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.35066 · Cited by 66
Tumor Compression of the Hepatic or Portal Vein Predicts the Presence of Microvascular Invasion and Satellite Nodules in Hepatocellular Carcinoma: A Retrospective Study
Wang, Q.-B., Luo, W.-L., Li, Y.-K., Li, J., Yang, Z.-S., Zhao, K., Lakang, Y., Liang, Y.-B., Chen, X., Zuo, J.-X., et al. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s544589 · Cited by 65
Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis
Fu, Y., Peng, W. J., Zhang, W., Yang, Z., Hu, Z., Pang, Y., Hu, D., Chen, J., Wang, J., Zhou, Z., et al. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-01976-x · Cited by 64
“& Minshan Chen chenmsh@sysucc.org.cn & Yaojun Zhang zhangyuj@sysucc.org.cn 1 Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, People’s Republic of China 2 Department of Liver Surgery, Sun Yat-Sen Uni…”
BackgroundResultInfluential
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Celsa, C., Cabibbo, G., Fulgenzi, C. A. M., Battaglia, S. L., Enea, M., Scheiner, B., D’Alessio, A., Manfredi, G. F., Stefanini, B., Nishida, N., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001026 · Cited by 73
Self-citation
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
Scheiner, B., Roessler, D., Phen, S., Lim, M., Pomej, K., Pressiani, T., Cammarota, A., Fründt, T., von Felden, J., Schulze, K., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100620 · Cited by 62
Self-citation
Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Kulkarni, A. V., Tevethia, H. V., Kumar, K., Premkumar, M., Muttaiah, M. D., Hiraoka, A., Hatanaka, T., Tada, T., Kumada, T., Kakizaki, S., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102179 · Cited by 61
Self-citation
Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial
Garin, É., Tselikas, L., Guiu, B., Chalaye, J., Rolland, Y., de Baère, T., Assénat, E., Tacher, V., Palard, X., Deandreis, D., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266211 · Cited by 61
Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies
Neil, V. M., & Lee, S. W. (2025) · Cancers · doi:10.3390/cancers17091408 · Cited by 67
“Liver transplantation, surgical resection, and local ablation are key approaches for managing early-stage HCC [43,45].”
The Current Role of Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma (HCC)
Kimura, T., Fujiwara, T., Kameoka, T., Adachi, Y., & Kariya, S. (2022) · Cancers · doi:10.3390/cancers14184383 · Cited by 66
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
Persano, M., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Cheon, J., Finkelmeier, F., Lim, H. Y., Presa, J., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.021 · Cited by 62
Changing Epidemiology of Hepatocellular Carcinoma Within the United States and Worldwide
Rich, N. E. (2023) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2023.06.004 · Cited by 60
From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention
Motta, B. M., Masarone, M., Torre, P., & Persico, M. (2023) · Cancers · doi:10.3390/cancers15225458 · Cited by 61
“…Clinic Liver Cancer) system used for staging liver cancer, takes into account the number and size of the tumor, the stage of the underlying liver disease (portal hypertension and Child–Pugh class) and the patient’s condition, dividing them into ﬁve stages: stages 0 and A, B, C, and D [140].”
TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC
Guiu, B., Garin, É., Allimant, C., Edeline, J., & Salem, R. (2022) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-022-03072-8 · Cited by 59
Self-citation
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials
Fulgenzi, C. A. M., D’Alessio, A., Airoldi, C. A., Scotti, L., Demirtaş, C. Ö., Gennari, A., Cortellini, A., & Pinato, D. J. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.058 · Cited by 60
Imaging Diagnosis of Hepatocellular Carcinoma: A State-of-the-Art Review
Candita, G., Rossi, S., Cwiklinska, K., Fanni, S. C., Cioni, D., Lencioni, R. A., & Neri, E. (2023) · Diagnostics · doi:10.3390/diagnostics13040625 · Cited by 61
“Indeed, due to the recent advances in the oncologic armamentarium, the Barcelona Clinic Liver Cancer (BCLC) treatment strategy was updated in 2022, including the latest evidence of promising medical and interventional therapies [10].”
Background
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice
Cabibbo, G., Celsa, C., Rimassa, L., Torres, F., Rimola, J., Kloeckner, R., Bruix, J., Cammà, C., & Reig, M. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.018 · Cited by 62
Self-citation
Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023
Akahoshi, K., Shindoh, J., Tanabe, M., Ariizumi, S., Eguchi, S., Okamura, Y., Kaibori, M., Kubo, S., Shimada, M., Taketomi, A., et al. (2024) · Liver Cancer · doi:10.1159/000538627 · Cited by 59
Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors
Montazeri, S. A., la Garza‐Ramos, C. D., Lewis, A. R., Lewis, J. T., LeGout, J. D., Sella, D. M., Paz‐Fumagalli, R., Devcic, Z., Ritchie, C. A., Frey, G. T., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05776-y · Cited by 58
Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study
Wu, J., Zhang, Z., Zhou, J., Ke, J.-P., Bai, Y.-N., Chen, Y., Wu, J., Zhou, S., Wang, S., Zeng, Z.-X., et al. (2022) · Liver Cancer · doi:10.1159/000528356 · Cited by 57
Recurrent Hepatocellular Carcinoma: Patterns, Detection, Staging and Treatment
Papaconstantinou, D., Tsilimigras, D. I., & Pawlik, T. M. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s342266 · Cited by 56
DNA methylation markers in the detection of hepatocellular carcinoma
Fu, S., Debes, J. D., & Boonstra, A. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.112960 · Cited by 57
Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study
Dekker, E. N., van Dam, J. L., Janssen, Q. P., Besselink, M. G., DeSilva, A., Doppenberg, D., van Eijck, C. H. J., Nasar, N. F., O'Reilly, E. M., Paniccia, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01311 · Cited by 56
“29 30-32 A recent study investigated 404 patients with PR and BR PDAC, who all underwent surgery as primary therapy.”
Background
Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future
Singal, A. G., Yarchoan, M. M., Yopp, A. C., Sapisochín, G., Pinato, D. J., & Pillai, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000430 · Cited by 55
Self-citation
Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials
Fulgenzi, C. A. M., Scheiner, B., Korolewicz, J., Stikas, C., Gennari, A., Vincenzi, B., Openshaw, M. R., Silletta, M., Pinter, M., Cortellini, A., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100702 · Cited by 54
Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma
Huang, D. Q., Hoang, J. K., Kamal, R., Tsai, P., Toyoda, H., Yeh, M., Yasuda, S., Leong, J., Maeda, M., Huang, C., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.00757 · Cited by 53
Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma
Singal, A. G., Salem, R., Pinato, D. J., & Pillai, A. A. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.047 · Cited by 56
Self-citation
Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study
Bo, Z., Chen, B., Zhao, Z., He, Q., Mao, Y., Yang, Y., Yao, F., Yang, Y., Chen, Z., Yang, J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2784 · Cited by 54
Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data
Wassmer, C., Hajji, S. E., Papazarkadas, X., Compagnon, P., Tabrizian, P., Lacotte, S., & Toso, C. (2023) · Cancers · doi:10.3390/cancers15184574 · Cited by 52
“Therapeutic strategies for HCC rely on the Barcelona Clinic Liver Cancer staging system [3].”
Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)
de Baère, T., Ronot, M., Chung, J. W., Golfieri, R., Kloeckner, R., Park, J., Gebauer, B., Kibriya, N., Ananthakrishnan, G., & Miyayama, S. (2022) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-022-03233-9 · Cited by 52
A Multi-centre, Single Arm, Non-randomized, Prospective European Trial to Evaluate the Safety and Efficacy of the HistoSonics System in the Treatment of Primary and Metastatic Liver Cancers (#HOPE4LIVER)
Wah, T. M., Pech, M., Thormann, M., Serres, X., Littler, P., Stenberg, B., Lenton, J., Smith, J. T., Wiggermann, P., Planert, M., et al. (2022) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-022-03309-6 · Cited by 52
Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma
He, M., Liu, Y., Chen, S., Deng, H., Feng, C., Qiao, S., Chen, Q., Hu, Y., Chen, H., Wang, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46118-w · Cited by 52
“Immunotherapies that block programmed death ligand-1 (PD-L1) checkpoints in combination with anti-angiogenesis or other checkpoints, such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), are currently recommended as ﬁ rst-line treat-ment for advanced HCC (aHCC) 2,3 .”
The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
Ke, Q., Xin, F., Fang, H., Zeng, Y., Wang, L., & Liu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.913464 · Cited by 51
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association
Allaire, M., Bruix, J., Korenjak, M., Manes, S., Maravic, Z., Reeves, H. L., Salem, R., Sangro, B., & Sherman, M. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100578 · Cited by 52
Self-citation
Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab
Campani, C., Bamba‐Funck, J., Campion, B., Sidali, S., Blaise, L., Ganne‐Carrié, N., Demory, A., Sutter, O., Larrey, E., Evain, M., et al. (2022) · Liver International · doi:10.1111/liv.15487 · Cited by 51
Complications Related to Transarterial Treatment of Hepatocellular Carcinoma: A Comprehensive Review
Lee, H. N., & Hyun, D. (2023) · Korean Journal of Radiology · doi:10.3348/kjr.2022.0395 · Cited by 51
“Current guidelines recommend transarterial treatment as the first-line treatment for intermediate-stage hepatocellular carcinoma (HCC) [1-4].”
Background
Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study
Zhang, W., Zhang, K., Liu, C., Gao, W., Si, T., Zou, Q., Guo, Z., Yang, X., Li, M., Liu, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127349 · Cited by 51
Glutamine metabolic reprogramming in hepatocellular carcinoma
Ye, Y., Yu, B., Wang, H., & Yi, F. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1242059 · Cited by 47
“, 2022a), and the expected survival of HCC with advanced stage could reach up to more than 2 years (Finn et al., 2020; Reig et al., 2022).”
Background
Locoregional Therapies for Hepatocellular Carcinoma
Patel, K. R., Menon, H., Patel, R. R., Huang, E. P., Verma, V., & Escorcia, F. E. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.47995 · Cited by 59
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study
Moeckli, B., Wassmer, C., Hajji, S. E., Kumar, R., Ribeiro, J. R., Tabrizian, P., Feng, H., Schnickel, G. T., Kulkarni, A. V., Allaire, M., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001289 · Cited by 51
Self-citation
Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis
Guo, Y., Ren, Y., Zhu, L., Yang, L., & Zheng, C. (2023) · Scientific Reports · doi:10.1038/s41598-022-27238-z · Cited by 50
Artificial intelligence in interventional radiology: state of the art
Glielmo, P., Fusco, S., Gitto, S., Zantonelli, G., Albano, D., Messina, C., Sconfienza, L. M., & Mauri, G. (2024) · European Radiology Experimental · doi:10.1186/s41747-024-00452-2 · Cited by 50
Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview
Matsuo, Y. (2023) · Current Oncology · doi:10.3390/curroncol30020190 · Cited by 49
“The Barcelona Clinic Liver Cancer (BCLC) recently updated its strategy paper for the prognosis and treatment of HCC [5].”
Background
Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review
Puisieux, M. F., Pellat, A., Assaf, A., Ginestet, C., Brézault, C., Dhooge, M., Soyer, P. A., & Coriat, R. (2022) · Cancers · doi:10.3390/cancers14102357 · Cited by 50
Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study
Kolligs, F. T., Arnold, D., Golfieri, R., Pech, M., Peynırcıoğlu, B., Pfammatter, T., Ronot, M., Sangro, B., Schaefer, N. G., Maleux, G. A., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100633 · Cited by 48
Self-citation
Vessels that encapsulate tumour clusters vascular pattern in hepatocellular carcinoma
Liu, K., Dennis, C. V., Prince, D. S., Marsh‐Wakefield, F., Santhakumar, C., Gamble, J. R., Strasser, S. I., & McCaughan, G. W. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100792 · Cited by 48
KLF6 alleviates hepatic ischemia-reperfusion injury by inhibiting autophagy
Li, J., Yu, D., He, C., Yu, Q., Huo, Z.-K., Zhang, Y., & Zhang, S. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05872-3 · Cited by 48
“Liver transplantation (LT) is an effective strategy for the treatment of liver cancer and end-stage liver diseases [1, 2].”
Magnetic Metal–Organic Framework-Based Nanoplatform with Platelet Membrane Coating as a Synergistic Programmed Cell Death Protein 1 Inhibitor against Hepatocellular Carcinoma
Guo, H., Liu, Y., Li, X., Wang, H., Mao, D., Wei, L., Ye, X., Qu, D., Huo, J., & Chen, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c07885 · Cited by 52
Precision surgery for hepatocellular carcinoma
Magyar, C. T. J., Rajendran, L., Li, Z., Banz, V. M., Vogel, A., O'Kane, G. M., Chan, A. C. Y., & Sapisochín, G. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00434-5 · Cited by 49
Self-citation
Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation
Kim, D.-S., Yoon, Y.-I., Kim, B. K., Choudhury, A., Kulkarni, A., Park, J. Y., Kim, J., Sinn, D. H., Joo, D. J., Choi, Y., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10629-3 · Cited by 47
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective
Su, T., Wu, C., Liu, T., Ho, C., & Liu, C. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0421 · Cited by 47
Comparison of Baseline68Ga-FAPI and18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib
Wu, M., Wang, Y., Yang, Q., Wang, X., Yang, X., Xing, H., Sang, X., Li, X., Zhao, H., & Huo, L. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265712 · Cited by 47
“In particular, the combination of immune checkpoint blockade (ICB) and multikinase inhibitors has gained remarkable successes in clinical settings ( 2 ).”
Adjuvant and neoadjuvant therapies for hepatocellular carcinoma
Vogel, A., Grant, R. C., Meyer, T., Sapisochín, G., O'Kane, G. M., & Saborowski, A. L. (2023) · Hepatology · doi:10.1097/hep.0000000000000726 · Cited by 53
Self-citation
Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma
Vitale, A., Romano, P., Cillo, U., Writing Group for the HE.RC.O.LE.S Collaborative Group, Writing Group for the ITA.LI.CA Collaborative Group, Groups, H. R. O. L. S. A. I. L. C. C., Busti, M., Nezi, G., Carlis, R. D., Ratti, F., et al. (2024) · JAMA Surgery · doi:10.1001/jamasurg.2024.1184 · Cited by 47
Impact of 68Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors
Kosmala, A., Serfling, S. E., Schlötelburg, W., Lindner, T., Michalski, K., Schirbel, A., Higuchi, T., Hartrampf, P. E., Buck, A. K., Weich, A., et al. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004480 · Cited by 47
Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA
Campani, C., Zucman‐Rossi, J., & Nault, J. (2023) · Cancers · doi:10.3390/cancers15030817 · Cited by 52
Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy
Hatanaka, T., Yata, Y., Naganuma, A., & Kakizaki, S. (2023) · Cancers · doi:10.3390/cancers15061798 · Cited by 47
“These two regimens (Atez/Bev and Dur/Tre) have shown promising results and have been recommended as first-line treatments in the latest BCLC staging system [31].”
Background
Transarterial Chemoembolization for Hepatocellular Carcinoma: 2023 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association
Cho, Y., Choi, J. W., Kwon, H., Kim, K. Y., Lee, B.-C., Chu, H. H., Lee, D. H., Lee, H. A., Kim, G. M., Oh, J. S., et al. (2023) · Korean Journal of Radiology · doi:10.3348/kjr.2023.0385 · Cited by 46
Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study
Guo, D., Huang, A., Wang, Y., Zhou, S., Wang, H., Xing, X., Zhang, S., Cheng, J., Xie, K., Yang, Q., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1652 · Cited by 45
“35,36 Thus, effective early screening and diagnosis play a pivotal role in improving disease prognosis.”
Background
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
Argenziano, M. E., Kim, M. N., Montori, M., Bucchianico, A. D., Balducci, D., Ahn, S. H., & Svegliati‐Baroni, G. (2024) · Hepatology International · doi:10.1007/s12072-024-10692-4 · Cited by 52
Self-assembling chemodrug fiber-hydrogel for transarterial chemoembolization and radiotherapy-enhanced antitumor immunity
Peng, Y., Liu, H., Liang, X., Cao, L., Teng, M., Chen, H., Li, Z., Peng, X., Mao, J., Cheng, H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.088 · Cited by 46
Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study
Roessler, D., Öcal, O., Philipp, A. B., Markwardt, D., Munker, S., Mayerle, J. V., Jochheim, L. S., Hammer, K., Lange, C. M., Geier, A., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04206-8 · Cited by 47
Thermal Ablation of Liver Tumors Guided by Augmented Reality: An Initial Clinical Experience
Solbiati, M., Ierace, T., Muglia, R., Pedicini, V., Iezzi, R., Passera, K. M., Rotilio, A., Goldberg, S. N., & Solbiati, L. (2022) · Cancers · doi:10.3390/cancers14051312 · Cited by 45
Rhein‐based Pickering emulsion for hepatocellular carcinoma: Shaping the metabolic signaling and immunoactivation in transarterial chemoembolization
Liang, X., Liu, H., Chen, H., Peng, X., Li, Z., Teng, M., Peng, Y., Li, J. Y., Ding, L., Mao, J., et al. (2024) · Aggregate · doi:10.1002/agt2.552 · Cited by 44
Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study
Chen, Y., Zhang, J., Hu, W., Li, X., Sun, K., Shen, Y., Zhang, M., Wu, J., Gao, S., Yu, J., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01991-1 · Cited by 44
“5,6 Transcatheter arterial chemoembolization (TACE), recommended as the ﬁ rst-line treatment for intermediate/advanced HCC. 4,7 However, repeated TACE may impair liver function and stimulate tumor angiogenesis by up-regulating the expression of vascular endothelial growth factor (VEGF), hence promoting tumor growth an…”
Influential
Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
Ouyang, T., Kan, X., & Zheng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.898964 · Cited by 43
The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma
Brandi, N., & Renzulli, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108598 · Cited by 43
“The Barcelona Clinic Liver Cancer Staging (BCLC) system is one of the most widely used, and takes into account hepatic function, the extent of tumor involvement, and performance status [3].”
BackgroundInfluential
2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations
Kumar, A., Acharya, S. K., Singh, S. P., Duseja, A. K., Madan, K., Shukla, A., Arora, A., Anand, A. C., Bahl, A., Soin, A. S., et al. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.08.005 · Cited by 43
Integrating single-cell and bulk RNA sequencing reveals CK19 + cancer stem cells and their specific SPP1 + tumor-associated macrophage niche in HBV-related hepatocellular carcinoma
Yang, C., Song, R. Y., Hu, J., Huang, J., Li, N., Ni, H.-H., Li, Y., Zhang, J., Lü, Z., Zhou, M., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10615-9 · Cited by 51
A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma
Zhu, W., Zhang, Z., Chen, J., Chen, X., Huang, L., Zhang, X., Huang, X., Ma, N., Xu, W., Yi, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01792-6 · Cited by 43
Non-alcoholic fatty liver disease-related hepatocellular carcinoma
Daher, D., Dahan, K. S. E., & Singal, A. G. (2023) · Journal of Liver Cancer · doi:10.17998/jlc.2022.12.30 · Cited by 45
Self-citation
Phenotypes of Metabolic Dysfunction–Associated Steatotic Liver Disease–Associated Hepatocellular Carcinoma
Rivera‐Esteban, J., Muñoz, S., Higuera, M., Sena, E., Bermúdez-Ramos, M., Bañares, J., Martínez-Gómez, M., Cusidó, M. S., Jiménez-Masip, A., Francque, S., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.028 · Cited by 45
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction
Fulgenzi, C. A. M., Scheiner, B., D’Alessio, A., Mehan, A., Manfredi, G. F., Celsa, C., Nishida, N., Ang, C., Marron, T. U., Wu, L. Y., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.2166 · Cited by 42
Self-citation
The current status and future of targeted-immune combination for hepatocellular carcinoma
Hao, L., Li, S., Ye, F., Wang, H., Zhong, Y., Zhang, X., Hu, X., & Huang, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1418965 · Cited by 49
All You Need to Know About TACE: A Comprehensive Review of Indications, Techniques, Efficacy, Limits, and Technical Advancement
Lanza, C., Ascenti, V., Amato, G. V., Pellegrino, G., Triggiani, S., Tintori, J., Intrieri, C., Angileri, S. A., Biondetti, P., Carriero, S., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020314 · Cited by 42
“Despite these developments, guidelines like the BCLC, AASLD, EASL, ESMO, and APASL recommend TACE over HAIC for HCC [9,98].”
Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
Chon, Y. E., Cheon, J., Kim, H., Kang, B., Ha, Y., Kim, D. Y., Hwang, S. G., Chon, H. J., & Kim, B. K. (2022) · Cancer Medicine · doi:10.1002/cam4.5161 · Cited by 43
Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation
Katariya, N., Lizaola‐Mayo, B., Chascsa, D. M. H., Giorgakis, E., Aqel, B. A., Moss, A. A., Usón, P. L. S., Borad, M. J., & Mathur, A. K. (2022) · Cancers · doi:10.3390/cancers14092056 · Cited by 41
Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation
Shi, Z., Duan, Y., Cui, F., Wu, Z.-J., Li, M.-P., Song, P., Peng, Q., Ye, W.-T., Yin, K.-L., Kang, M., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02716-y · Cited by 43
“However, RFA is not favored in cases with tumors larger than 2 cm, as this group has a lower rate of complete response and a higher recurrence rate than the group with smaller tumors [10].”
Background
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma
Bergamini, C., Leoni, I., Rizzardi, N., Melli, M., Galvani, G., Coadǎ, C. A., Giovannini, C., Monti, E., Liparulo, I., Valenti, F., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02718-w · Cited by 42
“Despite the combination of atezolizumab with bevacizumab is currently the first choice first-line treatment [61], not all patients can benefit from immunotherapy and, in the latter cases, sorafenib and lenvatinb represent the first line treatments of choice [62].”
Background
Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study
Sim, Y. K., Chong, M. C., Gandhi, M., Pokharkar, Y. M., Zhu, Y., Shi, L., Li, L., Chen, C., Kudo, M., Lee, J. H., et al. (2023) · Liver Cancer · doi:10.1159/000534513 · Cited by 41
HCC-Related lncRNAs: Roles and Mechanisms
Shah, M., & Sarkar, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010597 · Cited by 44
“Additionally, targeted therapies, including tyrosine kinase inhibitors (TKIs), like sorafenib and lenvatinib, continue to be integral in systemic HCC treatment [16].”
Background
Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma
Wang, M.-D., Diao, Y., Yao, L., Fan, Z., Wang, K.-C., Wu, H., Gu, L., Xu, J., Li, C., Lv, G., et al. (2024) · iLiver · doi:10.1016/j.iliver.2024.100083 · Cited by 42
“Moreover, HCC often develops in the context of chronic liver disease, which further complicates the management of this malignant tumor [5,6].”
Artificial intelligence in interventional radiology: Current concepts and future trends
Lesaunier, A., Khlaut, J., Dancette, C., Tselikas, L., Bonnet, B., & Boeken, T. (2024) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2024.08.004 · Cited by 50
Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma
Chiang, C., Chan, S.-K., Chiu, K. W.-H., Lee, F. A. S., Chen, W., Wong, N. S. M., Ho, R. L. M., Lee, V. W. Y., Man, K., Kong, F., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.4085 · Cited by 43
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy
Scheiner, B., Kang, B., Balcar, L., Radu, I.-P., Reiter, F. P., Adžić, G., Guo, J., Gao, X., Yuan, X., Cheng, L., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001163 · Cited by 42
Self-citation
Updated Efficacy and Safety Data from IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma
Roy, A. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.07.003 · Cited by 41
Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial
Shuen, T. W. H., Alunni‐Fabbroni, M., Öcal, E., Malfertheiner, P., Wildgruber, M., Schinner, R., Pech, M., Benckert, J., Sangro, B., Kuhl, C. K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0569 · Cited by 41
Self-citation
Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies
Pinto, E., Pelizzaro, F., Farinati, F., & Russo, F. P. (2023) · Medicina · doi:10.3390/medicina59061115 · Cited by 43
“IATs are the most widely used treatment for unresectable HCC, being the recommended first-line therapy for patients with intermediate-stage disease [72,73].”
Background
Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI
Borde, T., Nezami, N., Gaupp, F. M. L., Savic, L. J., Taddei, T. H., Jaffe, A., Strazzabosco, M., Lin, M., Durán, R., Georgiades, C. S., et al. (2022) · Radiology · doi:10.1148/radiol.212426 · Cited by 39
Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges
Teng, Y., Xie, S., Guo, P.-P., Deng, Z., Zhang, Z., Gao, W., Zhang, W., & Zhong, J. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00586 · Cited by 41
Nomogram Estimating Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma From Preoperative Gadoxetate Disodium‐Enhanced MRI
Chen, F., Du, M., Qi, X., Bian, L., Wu, D., Shuang-lin, Z., Wang, J., Zhou, Y., & Zhu, X. (2022) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28488 · Cited by 39
Critical Analysis of the Updated Barcelona Clinic Liver Cancer (BCLC) Group Guidelines
Tsilimigras, D. I., Aziz, H., & Pawlik, T. M. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12242-4 · Cited by 39
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results
Saeed, A., Park, R., Dai, J., Al-Rajabi, R. M. T., Kasi, A., Baranda, J. C., Williamson, S. K., Saeed, A., Ripp, J., Collins, Z. S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100916 · Cited by 37
Metabolic dysfunction‐associated steatotic liver disease has become the most common cause of hepatocellular carcinoma in Sweden : A nationwide cohort study
Vaz, J., Jepsen, P., Strömberg, U., Midlöv, P., Eriksson, B., Buchebner, D., & Hagström, H. (2024) · International Journal of Cancer · doi:10.1002/ijc.35097 · Cited by 38
Contrast-enhanced ultrasound-based AI model for multi-classification of focal liver lesions
Ding, W., Meng, Y., Ma, J., Pang, C., Wu, J., Tian, J., Yu, J., Liang, P., & Wang, K. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.011 · Cited by 40
Provision of Interventional Radiology Services 2023
Morgan, R., Haslam, P. J., McCafferty, I., Bryant, T., Clarke, C. G. D., McPherson, S. J., Wells, D., Gupta, Y., See, T. C., Lakshminarayan, R., et al. (2023) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-023-03600-0 · Cited by 38
Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment
Wu, Q., Pan, C., Zhou, Y., Wang, S., Xie, L., Zhou, W., Ding, L., Chen, T., Qian, J., Su, R., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000320 · Cited by 37
Harnessing function of EMT in hepatocellular carcinoma: From biological view to nanotechnological standpoint
Alqurashi, Y. E., Al‐Hetty, H. R. A. K., Ramaiah, P., Fazaa, A. H., Jalil, A. T., Alsaikhan, F., Gupta, J., Ramírez‐Coronel, A. A., Tayyib, N. A., & Peng, H. (2023) · Environmental Research · doi:10.1016/j.envres.2023.115683 · Cited by 40
Diagnostic and Prognostic Value of Protein Post-Translational Modifications in Hepatocellular Carcinoma
Wang, J., Wang, F., Wang, N., Zhang, M., Wang, H., & Huang, G. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00006s · Cited by 37
Current Trends in Surgical Management of Hepatocellular Carcinoma
Angeli‐Pahim, I., Chambers, A., Duarte, S., & Zarrinpar, A. (2023) · Cancers · doi:10.3390/cancers15225378 · Cited by 40
“Overall, minimally invasive procedures reduce surgical stress, improve patient recovery, and should be considered whenever feasible [5].”
BackgroundMethodInfluential
Potential targets and therapeutics for cancer stem cell-based therapy against drug resistance in hepatocellular carcinoma
Zhao, H., Ling, Y., He, J., Dong, J., Mo, Q., Wang, Y., Zhang, Y., Hongbin, Y., & Tang, C. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101084 · Cited by 38

Authors: Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., Sangro, B., Singal, A. G., Vogel, A., Fuster, J., Ayuso, C., & Bruix, J.
Affiliations: Hospital Clínic de Barcelona (ES)
University of California, San Francisco (US)
University Medical Center of the Johannes Gutenberg University Mainz (DE)
University of Milan (IT)
Northwestern University (US)
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
The University of Texas Southwestern Medical Center (US)
Medizinische Hochschule Hannover (DE)
Corresponding author: Bruix, Jordi
ORCID: Reig, Maria
Forner, Alejandro
Rimola, Jordi
Burrel, Marta
Garcia-Criado, Ángeles
Kelley, Robin K.
Galle, Peter R.
Mazzaferro, Vincenzo
Salem, Riad
Sangro, Bruno
Singal, Amit G.
Vogel, Arndt
Fuster, Josep
Ayuso, Carmen
Bruix, Jordi
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2022-03
Volume: 76
Issue: 3
Pages: 681-693
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2021.11.018
PMC: PMC8866082
OpenAlex: W3213277274
Cited by: 4,319
References: 136
Citations by year: 2026: 684 · 2025: 1071 · 2024: 1166 · 2023: 962 · 2022: 424
FWCI: 83.72
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
eScholarship (California Digital Library) (submittedVersion)
Funders: Fundación Científica de la Asociación Española Contra el Cáncer (PI044031)
National Institutes of Health (R01 R01 MD012565, PI18/00768)
Horizon 2020 Framework Programme (952103)
Instituto de Salud Carlos III (AC16/00065, PI18/0358, PI15/00145, PI18/00542, PI19/00742, PI18/00768)
European Association for the Study of the Liver
Horizon 2020
Topics: Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords: hepatocellular carcinoma, Barcelona Clinic Liver Cancer staging, outcome prediction, treatment guidelines, evidence-based clinical decision-making
MeSH terms: Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Severity of Illness Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks